Table 1.
Patient Demographics And Disease-Specific Characteristics
| Characteristic | Ablation (N=45) | Surveillance (N=125) | P value |
|---|---|---|---|
|
| |||
| By Center | |||
|
| |||
| Univ. of Pennsylvania | 5 (11.1) | 53 (42.4) | <0.001 |
| Columbia | 10 (22.2) | 37 (29.6) | 0.34 |
| Mayo Clinic | 30 (66.7) | 35 (28) | <0.001 |
|
| |||
| Age, median (IQR), y | 62 (56, 58) | 65 (56, 73) | 0.15 |
|
| |||
| Men, No. (%) | 36 (80) | 103 (82.4) | 0.44 |
|
| |||
| White race/ethnicity, No. (%) | 43 (95.6) | 121 (96.8) | 0.50 |
|
| |||
| BMI, median (IQR)* | 28.9 (27, 32.2) | 28.5 (26.2, 31.7) | 0.39 |
|
| |||
| Tobacco use, No. (%)* | |||
|
| |||
| Current at time of dx | 5 (13.2) | 6 (7.1) | 0.23 |
| Non-current | 33 (86.8) | 78 (92.9) | |
|
| |||
| Use of Proton Pump Inhibitor, No. (%)* | |||
|
| |||
| Non-user | 1 (2.5) | 23 (26.7) | <0.001 |
| User** | 39 (97.5) | 63 (73.3) | |
|
| |||
| Use of Aspirin, No. (%)* | |||
|
| |||
| Non-user | 22 (56.4) | 51 (62.2) | 0.54 |
| User# | 17 (43.6) | 31 (37.8) | |
|
| |||
| Length of Barrett’s esophagus, median (IQR) | 5 (3, 6) | 5 (3, 8) | 0.42 |
|
| |||
| Presence of Nodularity, No. (%) | 3 (6.6) | 13 (10.4) | 0.45 |
|
| |||
| Multifocal dysplasia^, No. (%) | 19/45 (42.2) | 28/84 (33.3) | 0.13 |
|
| |||
| Incident cases^^, No. (%) | 19/45 (42.2) | 57/90 (63.3) | 0.02 |
|
| |||
| Confirmed with Second Pathology Specimen°, No. (%) | 27/45 (60) | 43/90 (47.8) | 0.14 |
|
| |||
| Follow-up period per patient, months, median (IQR)¶ | 29.6 (8.8, 54.1) | 28.3 (10.7, 78.5) | 0.32 |
|
| |||
| Total endoscopies performed during follow-up period per patient, No., median (IQR) | 9 (6, 12) | 5 (3, 8) | <0.001 |
Sample sizes with complete data for BMI: n=37 [ablation], n=75 [surveillance]; for Tobacco use: n=38 [ablation], n=84 [surveillance]; for Proton Pump Inhibitor use: n=40 [ablation], n=86 [surveillance]; aspirin use: n=39 [ablation], n=82 [surveillance]
All users on twice daily PPI except 3 patients in ablated group and 20 in the surveillance group.
All users on low dose aspirin (81 mg) except one patient in the ablated group and two patients in the surveillance group on full dose aspirin (325 mg).
Data for multifocality available in only 84 surveillance patients, not able to be determined in 35 patients in historical cohort from Mayo, 6 other patients had biopsies placed in same specimen jar.
At least one endoscopy with biopsies documenting Barrett’s without dysplasia preceding diagnosis of LGD during the study period. Recorded in all ablated patients and 90 surveillance patients, not able to be determined in 35 patients in historical cohort from Mayo.
°At least two endoscopies with biopsies documenting Barrett’s with LGD during study period. Data for this variate available in only 90 surveillance patients, not able to be determined in 35 patients in historical cohort from Mayo.
Time from initial intervention (first RFA or surveillance EGD) to progression or last endoscopy with biopsies in chart